DB:4DN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States.


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Denali Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 4DN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.6%

4DN

-3.2%

DE Biotechs

0.05%

DE Market


1 Year Return

23.5%

4DN

3.3%

DE Biotechs

3.4%

DE Market

Return vs Industry: 4DN exceeded the German Biotechs industry which returned 8.7% over the past year.

Return vs Market: 4DN exceeded the German Market which returned 4.5% over the past year.


Shareholder returns

4DNIndustryMarket
7 Day-1.6%-3.2%0.05%
30 Day-0.3%4.5%5.5%
90 Day18.9%14.7%19.9%
1 Year23.5%23.5%3.5%3.3%5.7%3.4%
3 Yearn/a15.8%14.4%3.4%-4.7%
5 Yearn/a9.4%7.7%10.4%-4.5%

Price Volatility Vs. Market

How volatile is Denali Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Denali Therapeutics undervalued compared to its fair value and its price relative to the market?

4.99x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 4DN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 4DN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 4DN is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: 4DN is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4DN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 4DN is overvalued based on its PB Ratio (5x) compared to the DE Biotechs industry average (2.9x).


Next Steps

Future Growth

How is Denali Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

-1.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4DN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 4DN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 4DN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 4DN's revenue (49.5% per year) is forecast to grow faster than the German market (5.9% per year).

High Growth Revenue: 4DN's revenue (49.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 4DN is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Denali Therapeutics performed over the past 5 years?

-23.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4DN is currently unprofitable.

Growing Profit Margin: 4DN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 4DN is unprofitable, and losses have increased over the past 5 years at a rate of -23.7% per year.

Accelerating Growth: Unable to compare 4DN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4DN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.8%).


Return on Equity

High ROE: 4DN has a negative Return on Equity (-39.5%), as it is currently unprofitable.


Next Steps

Financial Health

How is Denali Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 4DN's short term assets ($604.8M) exceed its short term liabilities ($47.6M).

Long Term Liabilities: 4DN's short term assets ($604.8M) exceed its long term liabilities ($102.9M).


Debt to Equity History and Analysis

Debt Level: 4DN is debt free.

Reducing Debt: 4DN has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 4DN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 4DN has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 17.8% each year.


Next Steps

Dividend

What is Denali Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 4DN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 4DN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 4DN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 4DN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 4DN's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Ryan Watts (44yo)

4.92yrs

Tenure

US$4,978,607

Compensation

Dr. Ryan J. Watts, Ph.D. is the Co-Founder of Denali Therapeutics Inc. and has been its President and Chief Executive Officer since August 2015. Dr. Watts has been a Director of Denali Therapeutics Inc. si ...


CEO Compensation Analysis

Compensation vs Market: Ryan's total compensation ($USD4.98M) is above average for companies of similar size in the German market ($USD2.41M).

Compensation vs Earnings: Ryan's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Ryan Watts
Co-Founder4.92yrsUS$4.98m2.28% $52.6m
Alexander Schuth
Co-Founderno dataUS$2.48m0.59% $13.5m
Marc Tessier-Lavigne
Co-Founderno dataUS$405.08k2.59% $59.8m
Steve Krognes
CFO & Treasurer4.75yrsUS$2.53m0.95% $22.0m
Carole Ho
Chief Medical Officer & Head of Development5.08yrsUS$2.49m0.15% $3.4m
Dana Andersen
Chief Technical and Manufacturing Officer1.92yrsno datano data
Zach Sweeney
Chief Scientific Officer0.67yrno datano data
Chris Walsh
Vice President of Legal1.5yrsno datano data
Cindy Dunkle
Chief People Officerno datano datano data
Joe Lewcock
Head of Biology Discoveryno datano datano data
Dolo Diaz
Head of Development Sciences1.5yrsno datano data
Tony Estrada
Head of Small Molecule Discovery0.50yrno datano data

1.7yrs

Average Tenure

47yo

Average Age

Experienced Management: 4DN's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Ryan Watts
Co-Founder4.92yrsUS$4.98m2.28% $52.6m
Marc Tessier-Lavigne
Co-Founderno dataUS$405.08k2.59% $59.8m
Robert Taylor Nelsen
Independent Director5.17yrsUS$395.08k0.0019% $44.3k
Vicki Sato
Independent Chairperson3.92yrsUS$428.08k0.13% $3.0m
Jay Flatley
Independent Director5.25yrsUS$402.58k0.31% $7.1m
David Schenkein
Independent Director5.25yrsUS$404.08k0.31% $7.1m
David Holtzman
Member of Scientific Advisory Boardno datano datano data
Peter Klein
Independent Director2.33yrsUS$405.08kno data
Scott Biller
Member of Scientific Advisory Boardno datano datano data
Douglas Cole
Independent Director5.17yrsUS$402.58kno data
Leonard Petrucelli
Member of Scientific Advisory Boardno datano datano data
Alison Goate
Member of Scientific Advisory Boardno datano datano data

5.2yrs

Average Tenure

60yo

Average Age

Experienced Board: 4DN's board of directors are considered experienced (5.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 4DN insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.6%.


Top Shareholders

Company Information

Denali Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Denali Therapeutics Inc.
  • Ticker: 4DN
  • Exchange: DB
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.621b
  • Listing Market Cap: US$2.306b
  • Shares outstanding: 105.63m
  • Website: https://www.denalitherapeutics.com

Number of Employees


Location

  • Denali Therapeutics Inc.
  • 161 Oyster Point Boulevard
  • 2nd Floor
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4DNMUN (Boerse Muenchen)YesCommon StockDEEURDec 2017
DNLINasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDDec 2017
4DNDB (Deutsche Boerse AG)YesCommon StockDEEURDec 2017

Biography

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson’s disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson’s disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer’s disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Further, it has various seed programs under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/14 21:44
End of Day Share Price2020/07/14 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.